Immatics NV (IMTX)vsInsmed Inc (INSM)
IMTX
Immatics NV
$9.74
+5.87%
HEALTHCARE · Cap: $1.31B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1156% more annual revenue ($606.42M vs $48.27M). IMTX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
IMTX
Avoid25
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Grey zone — moderate risk
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IMTX
The strongest argument for IMTX centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : IMTX
The primary concerns for IMTX are EPS Growth, Altman Z-Score, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
IMTX profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
IMTX carries more volatility with a beta of 1.35 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
IMTX generates stronger free cash flow (-59M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immatics NV
HEALTHCARE · BIOTECHNOLOGY · USA
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?